CN115427042A - 组合 - Google Patents

组合 Download PDF

Info

Publication number
CN115427042A
CN115427042A CN202080095235.7A CN202080095235A CN115427042A CN 115427042 A CN115427042 A CN 115427042A CN 202080095235 A CN202080095235 A CN 202080095235A CN 115427042 A CN115427042 A CN 115427042A
Authority
CN
China
Prior art keywords
unsubstituted
substituted
group
alkyl
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080095235.7A
Other languages
English (en)
Chinese (zh)
Inventor
艾哈迈德·阿布迪·萨玛塔
李佳莉
胡曼·伊扎迪
黄琴华
布伦特·克莱顿·博伦
约瑟夫·罗伯特·平奇曼
凯文·杜安·邦克
费尔南多·多纳特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ricoram Ip Holding Co ltd
Original Assignee
Ricoram Ip Holding Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ricoram Ip Holding Co ltd filed Critical Ricoram Ip Holding Co ltd
Publication of CN115427042A publication Critical patent/CN115427042A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Glass Compositions (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Steroid Compounds (AREA)
CN202080095235.7A 2019-12-20 2020-12-16 组合 Pending CN115427042A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962952039P 2019-12-20 2019-12-20
US62/952,039 2019-12-20
PCT/US2020/065409 WO2021127044A1 (en) 2019-12-20 2020-12-16 Combinations

Publications (1)

Publication Number Publication Date
CN115427042A true CN115427042A (zh) 2022-12-02

Family

ID=76478095

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080095235.7A Pending CN115427042A (zh) 2019-12-20 2020-12-16 组合

Country Status (12)

Country Link
US (1) US20230008362A1 (https=)
EP (1) EP4069235A4 (https=)
JP (1) JP7631348B2 (https=)
KR (1) KR20220119442A (https=)
CN (1) CN115427042A (https=)
AU (1) AU2020407070A1 (https=)
BR (1) BR112022012281A2 (https=)
CA (1) CA3165472A1 (https=)
IL (1) IL294080A (https=)
MX (1) MX2022007626A (https=)
TW (1) TW202132299A (https=)
WO (1) WO2021127044A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4566612A3 (en) 2018-03-09 2025-08-20 Recurium IP Holdings, LLC Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones
AU2020384291A1 (en) 2019-11-15 2022-05-26 Recurium Ip Holdings, Llc Chiral synthesis of a tertiary alcohol
WO2022011391A1 (en) 2020-07-09 2022-01-13 Recurium Ip Holdings, Llc Salts and forms of a wee1 inhibitor
EP4431511A4 (en) * 2021-11-09 2025-10-15 Hangzhou Glubio Pharmaceutical Co Ltd WEE1 PROTEIN KINASE DEGRADING AGENT AND ITS USE
WO2023114877A1 (en) * 2021-12-15 2023-06-22 Recurium Ip Holdings, Llc Triple therapy combinations of bcl-2 inhibitors, wee-1 inhibitors and other chemotherapeutic agents
WO2025193930A1 (en) * 2024-03-14 2025-09-18 Zeno Management, Inc. Wee1 inhibitor combination therapy

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019028008A1 (en) * 2017-08-01 2019-02-07 Zeno Royalties & Milestones, LLC 1,2-DIHYDRO-3H-PYRAZOLO [3,4-D] PYRIMIDIN-3-ONE ANALOGUES
CN109422754A (zh) * 2017-08-24 2019-03-05 上海迪诺医药科技有限公司 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用
WO2019139899A1 (en) * 2018-01-10 2019-07-18 Zeno Royalties & Milestones, LLC Benzamide compounds
WO2019173082A1 (en) * 2018-03-09 2019-09-12 Zeno Royalties & Milestones, LLC Substituted l,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017517520A (ja) 2014-05-29 2017-06-29 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｗｅｅ１阻害剤を用いた癌を処置する方法
EP3694861A4 (en) * 2017-10-09 2021-05-19 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS AND USES THEREOF
WO2023114877A1 (en) * 2021-12-15 2023-06-22 Recurium Ip Holdings, Llc Triple therapy combinations of bcl-2 inhibitors, wee-1 inhibitors and other chemotherapeutic agents

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019028008A1 (en) * 2017-08-01 2019-02-07 Zeno Royalties & Milestones, LLC 1,2-DIHYDRO-3H-PYRAZOLO [3,4-D] PYRIMIDIN-3-ONE ANALOGUES
CN109422754A (zh) * 2017-08-24 2019-03-05 上海迪诺医药科技有限公司 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用
WO2019139899A1 (en) * 2018-01-10 2019-07-18 Zeno Royalties & Milestones, LLC Benzamide compounds
WO2019173082A1 (en) * 2018-03-09 2019-09-12 Zeno Royalties & Milestones, LLC Substituted l,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GEENEN, J.J.J.ET AL.: ""Molecular Pathways: Targeting the Protein Kinase Weel in Cancer"", 《CLINICAL CANCER RESEARCH》, vol. 23, no. 16, 15 March 2017 (2017-03-15), pages 4540 - 4544, XP055843092, DOI: 10.1158/1078-0432.CCR-17-0520 *
PERINI, G.F.ET AL: ""BCL-2 as therapeutic target for hematological malignancies"", 《JOURNAL OF HEMATOLOGY & ONCOLOGY》, vol. 11, no. 65, 11 May 2018 (2018-05-11), pages 1 - 15, XP002797218, DOI: 10.1186/s13045-018-0608-2 *

Also Published As

Publication number Publication date
TW202132299A (zh) 2021-09-01
JP2023508328A (ja) 2023-03-02
WO2021127044A1 (en) 2021-06-24
KR20220119442A (ko) 2022-08-29
US20230008362A1 (en) 2023-01-12
EP4069235A1 (en) 2022-10-12
JP7631348B2 (ja) 2025-02-18
AU2020407070A1 (en) 2022-07-14
BR112022012281A2 (pt) 2022-08-30
CA3165472A1 (en) 2021-06-24
EP4069235A4 (en) 2024-01-10
IL294080A (en) 2022-08-01
MX2022007626A (es) 2022-09-23

Similar Documents

Publication Publication Date Title
CN115427042A (zh) 组合
JP7750526B2 (ja) 組み合わせ
JP2023508325A (ja) 組み合わせ
JP2023508327A (ja) 組み合わせ
CN115038450A (zh) 组合
JP2023508331A (ja) 組み合わせ
JP2023507799A (ja) 組み合わせ
RU2840819C1 (ru) Комбинации
CN115666574A (zh) 组合
CN115023228A (zh) 组合
CN116744919A (zh) Bcl-2抑制剂与化疗药的组合

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20221202

WD01 Invention patent application deemed withdrawn after publication